Sub group | ARNi n (%) | Valsartan n (%) | Hazard Ratio | p-value |
Age |
|
|
|
|
<65 years | 31 (62) | 25 (50) |
|
|
≥65 years | 19 (38) | 25 (50) | 1.00 (0.79 1.86) | 0.997 |
Age |
|
|
|
|
<75 years | 41 (82) | 41 (82) |
|
|
≥75 years | 9 (18) | 9 (18) | 0.48 (0.42 2.62) | 0.326 |
Sex |
|
|
|
|
Male | 33 (66) | 16 (32) |
|
|
Female | 17 (34) | 34 (68) | 0.60 (0.15 2.41) | 0.475 |
NYHA class |
|
|
|
|
II | 1 (2) | 4 (8) |
|
|
III or IV | 49 (98) | 46 (92) | 0.51 (0.57 0.82) | 0.047 |
Estimated e GFR |
|
|
|
|
<60 ml/min/1.73 m2 | 34 (68) | 37 (74) |
|
|
≥60 ml/min/1.73 m2 | 16 (32) | 13 (26) | 0.17 (0.26 1.14) | 0.076 |
LA Diameter |
|
|
|
|
≤Median | 9 (25) | 12 (31.6) |
|
|
>Median | 27 (75) | 26 (68.4) | 1.77 (0.23 3.19) | 0.579 |
LVIDD |
|
|
|
|
≤Median | 25 (50) | 27 (54) |
|
|
>Median | 25 (50) | 23 (46) | 1.47 (0.22 9.78) | 0.688 |
LVIDS |
|
|
|
|
≤Median | 24 (48) | 33 (66) |
|
|
>Median | 26 (52) | 17 (34) | 0.30 (0.04 2.07) | 0.222 |
Ejection fraction (%) |
|
|
|
|
≤Median | 28 (56) | 26 (52) |
|
|
>Median | 22 (44) | 24 (48) | 0.14 (0.03 0.79) | 0.034 |
NT-proBNP (pg/ml) |
|
|
|
|
≤Median | 22 (44) | 28 (56) |
|
|
>Median | 28 (56) | 22 (44) | 9.01 (1.10 3.56) | 0.040 |